Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Elanco Animal Health Incorporated (ELAN) vs Teva Pharmaceutical Industries Ltd. (TEVA)

Elanco Animal Health Incorporated and Teva Pharmaceutical Industries Ltd. are both Drug Manufacturers Specialty & Generic companies. Teva Pharmaceutical Industries Ltd. is the larger, with a market value of $46.9B against $11.2B — 4.2× the size. Elanco Animal Health Incorporated has negative trailing earnings, so its P/E is not meaningful; Teva Pharmaceutical Industries Ltd. trades at 62.2×. Elanco Animal Health Incorporated grew revenue faster over the last twelve months: 12.0% against 4.13%. Teva Pharmaceutical Industries Ltd. has the higher net margin (4.08% vs −3.96%) and the higher return on invested capital (4.58% vs 0.51%). Across the 20 metrics below, Elanco Animal Health Incorporated leads on 11 and Teva Pharmaceutical Industries Ltd. on 9.

Valuation

Metric ELAN TEVA Drug Manufacturers Specialty & Generic median
P/E n/m 62.21 20.14
P/S 2.22 2.64 2.25
P/B 1.69 5.89 1.90
Price to free cash flow 31.22 32.59 16.54
EV/EBITDA 18.78 23.38 12.29
EV/Sales 2.89 3.38 2.56
Earnings yield (1.84%) 1.61% (2.99%)
Free cash flow yield 3.20% 3.07% 0.00%

Profitability

Metric ELAN TEVA Drug Manufacturers Specialty & Generic median
Gross margin 55.36% 52.46% 53.94%
Operating margin 1.61% 8.77% 0.00%
Net margin (3.96%) 4.08% 0.00%
Free cash flow margin 7.55% 8.09% 0.00%
Return on equity (2.98%) 9.69% (0.40%)
Return on assets (1.46%) 1.77% (3.32%)
Return on invested capital 0.51% 4.58% 0.00%

Growth

Metric ELAN TEVA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 11.95% 4.13% 10.01%
EPS growth (last fiscal year) (169.12%) 183.45% —
Revenue growth, 5-year CAGR 7.59% 0.71% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ELAN TEVA Drug Manufacturers Specialty & Generic median
Debt to equity 0.59 2.14 0.05
Current ratio 2.05 0.88 2.31
Net debt to EBITDA 5.00 4.19 0.85

Dividend

Metric ELAN TEVA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric ELAN TEVA Drug Manufacturers Specialty & Generic median
Market cap 11.21b 46.87b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack